High Demand for Non-invasive NASH Treatment to Augment Market

Over the past couple of decades, the number of obesity, diabetes, and non-alcoholic fatty liver diseases (NAFLD) cases have increased at a rapid pace. The range of NAFLD extends from steatosis to non-alcoholic steatohepatitis (NASH). The rise in the prevalence of NAFLD has caused a great amount of economic burden on nations worldwide and as per trends, patients suffering from NAFLD-related diseases have emerged as one of the major subset of people requiring liver transplant. One of the major factors that is likely to propel the adoption of NASH biomarker is the high prevalence of NAFLD and the undesirable outcomes. The adoption of conventional techniques to address NAFLD such as biopsy is steadily declining due to limitations, including sampling bias, complications such as pain, bleeding, mortality, and poor acceptability.

The demand for non-invasive techniques to treat NAFLD has witnessed a consistent growth over the past decade. Non-invasive techniques that have gained significant popularity to combat NAFLD include NASH, NAFLD-based fibrosis, and steatosis, among others. The surge in demand for these non-invasive techniques is expected to boost the demand for NASH biomarkers during the forecast period. In recent times, players operating in the global NASH biomarkers are increasingly investigating the algorithms that consist non-imaging and imaging biomarkers to diagnose fibrosis and minimize biopsies in clinical settings. Technological advancements, research and development activities coupled with high prevalence of NAFLD are some of major factors that are likely to drive the expansion of the non-alcoholic steatohepatitis (NASH) biomarkers market during the assessment period. At the back of these factors, the global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to attain a market value of ~US$ 2 Bn by the end of 2027.

non alcoholic steatohepatitis biomarkers market Infographic

To know the scope of our report Get a Sample on Non-alcoholic Steatohepatitis (NASH) Biomarkers Market

Adoption of NASH Biomarkers to Address Idiopathic Pulmonary Fibrosis

Advancements in the healthcare sector, along with research activities are likely to play a key role in the growth of the global non-alcoholic steatohepatitis (NASH) biomarkers market. In recent times, a considerable amount of research has been undertaken in discovering the potential treatments for idiopathic pulmonary fibrosis (IPF). In the past decade, the progression from NAFLD to NASH has increased at a rapid pace and has emerged as one of the most prevalent chronic liver conditions particularly in the Western regions, including North America and Europe– a factor due to which the production of NASH biomarkers is set to witness a considerable growth.

Get a glimpse of the in-depth analysis through our Report Brochure

At present, while researchers are increasingly focusing on improving the efficacy of NASH biomarkers, healthcare providers, medical professionals, and healthcare workers are projected to increase awareness regarding NASH. Medical experts are of the opinion that the prevalence of NASH is set to grow at a rapid pace in the coming decade due to which, robust measures are required to combat the same. Public health groups, along with government organizations particularly in developed regions are focusing on formulating new guidelines that govern the management of NASH. Innovations within the non-alcoholic steatohepatitis (NASH) biomarkers market are primarily targeting improvements in non-invasive screening and diagnostic testing. In addition, companies operating in the current market landscape are increasingly focusing on different molecules for the treatment of NASH. Moreover, at present, while a large number of drugs are in phase three trials, multiple drugs are in the pipeline across world. Companies operating in the current market landscape are primarily focusing on replacing painful and invasive biopsies with non-invasive NASH biomarkers. The launch of the new project by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium aimed toward standardizing biological markers to improve the diagnosis of NASH. The Non-Invasive Biomarkers of Metabolic Liver Disease project is expected to make a direct comparison between conventional and non-conventional techniques to address NASH and suggest the best tools to diagnose NASH. Such projects are expected to promote the sales of NASH biomarkers during the forecast period and thus, will augment the growth of the non-alcoholic steatohepatitis (NASH) biomarkers market.

Companies Adapt, Adjust, and Assess Pipeline Products, Seek FDA Approval

The advent of the novel coronavirus pandemic is expected to create major roadblocks for companies operating in the current non-alcoholic steatohepatitis (NASH) biomarkers market. Mobilization of researchers, front-line clinicians, manufacturers, and other participants in the value chain has emerged as a major area of concern amidst the chaos. On the heels of the health and economic crisis worldwide, The Global Liver Institute, recently revealed its plans to address the global pandemic by adapting and provide creative solutions. While supply chains within the non-alcoholic steatohepatitis (NASH) biomarkers market are likely to be disrupted, companies should focus on formulating effective business continuity strategies and focus on product diversification to address the business challenges put forward by the global pandemic.

non alcoholic steatohepatitis biomarkers market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

The global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to grow at a staggering CAGR of ~21% during the forecast period. The market growth can be attributed to a host of factors, including high demand for non-invasive techniques to address NASH, research and development activities, government support for the development of NASH biomarkers, and high focus on curbing the prevalence of diabetes and NAFLD. Market players are anticipated to focus on the development of new NASH biomarkers and attain the approval from the FDA. Moreover, North America and Europe are likely to be the hotbeds of development within the global non-alcoholic steatohepatitis (NASH) biomarkers market.  

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Overview

  • The global non-alcoholic steatohepatitis (NASH) biomarkers market was valued at ~US$ 300 Mn in 2018 and is projected to expand at a rapid pace from 2019 to 2027. Rise in NAFLD and NASH conditions; increase in patient pool suffering from obesity and metabolic diseases; rise in geriatric population; growth in Type 2 diabetes and pre-diabetes in adult patients; surge in demand for non-invasive diagnostic techniques; and increase in awareness about NASH condition and innovative diagnosis tools, especially in developing markets, are anticipated to propel the global non-alcoholic steatohepatitis (NASH) biomarkers market. 
  • NASH, also known as non-alcoholic steatohepatitis, is a progressive form of non alcoholic fatty liver disease (NAFLD). NAFLD is a condition in which fat is accumulated in the liver and the continuous fat deposition may cause liver inflammation and liver cell damage. This is termed as NASH condition. Increase in worldwide prevalence of obesity, type 2 diabetes, pre-diabetes, and metabolic diseases are major reasons for increase in prevalence of non-alcoholic steatohepatitis condition. Thus, innovative diagnostic tools are introduced in the market to accurately diagnose the non-alcoholic steatohepatitis condition. Liver biopsy is one of the standard tools for diagnosis of NASH condition. However, due to high cost of this procedure, many companies have introduced biomarkers as a diagnostic tool for NASH patients. Various non-invasive biomarkers are available for detection of the NASH condition, including serum biomarkers, biomarker panels, fibrosis biomarkers, imaging biomarkers, gene biomarkers, oxidative stress biomarkers, and Cytokeratin-18.
  • As per research, worldwide prevalence of NASH is estimated to be in a range of 1.5%–6.45%, respectively, in 2019. NASH prevalence across globe is expected to grow by 63% by 2030. Several pharmaceutical and biotechnology companies are investing in development of therapeutics for NASH. Currently, 95 drug candidates from different players are in pipeline ranging from preclinical to phase 3 trials. These players would require NASH biomarker diagnostics to monitor and evaluate drug effectiveness during clinical trials. Various companies have entered into collaboration to further strengthen and develop biomarkers, thereby augmenting the NASH biomarkers market in the near future.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Segmentation

  • The global non-alcoholic steatohepatitis (NASH) biomarkers market has been segmented based on biomarker type, end user, and region
  • In terms of biomarker, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been classified into serum biomarkers, biomarker panels, fibrosis biomarkers, imaging biomarkers, and others. The serum biomarkers segment is further classified into cytokeratin-18 (CK 18) marker, inflammatory markers, and others. The serum biomarkers segment held a largest market share, owing to availability of various tests in the market. The segment also has higher accuracy in differentiating NASH indications. Cell apoptosis increases during the progression of NASH. Markers such as fragments of cytokeratin-18 and ferritin are measured and found to be promising markers of NASH. CK-18 is considered as the popular and potential biomarker for detecting NASH indication. The others segment includes gene biomarkers and oxidative stress biomarkers which offer promising results in terms of higher accuracy and are considered to be inexpensive and simple non-invasive techniques.
  • In terms of end user, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been segregated into hospitals, diagnostic centers, and others. The diagnostic centers segment dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018, owing to increase in awareness about the NASH indication for early diagnosis followed by its effective treatment. Availability of technically advanced tools such as biomarkers tests in diagnostic centers coupled with presence of expertise is likely to drive the diagnostic centers segment.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Regional Segmentation

  • In terms of region, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018, owing to rise in prevalence of NASH associated conditions such as obesity and type 2 diabetes in the region. Several market players such as Quest Diagnostics for Hepascore and Exalenz Biosciences Ltd. are opting to enter North America through collaborations and alliances. Demand for non-invasive diagnostic tests for NASH and related diseases is high due to accuracy and operational limitations and associated hazards of liver biopsy. Rise in adoption of minimal invasive surgeries, growing geriatric population, and investments by key players in R&D to develop innovative and promising biomarkers are estimated to boost the non-alcoholic steatohepatitis (NASH) biomarkers market in the region.
  • The non-alcoholic steatohepatitis (NASH) biomarkers market in Latin America and Middle East & Africa is anticipated to expand at a faster pace than other regions during the forecast period. Rising patient population suffering from NASH condition is a major factor likely to propel the market in Latin America and the Middle East. Latin America likely to exhibit highest CAGR, owing to prevalence of NASH condition. For instance, in Brazil, the prevalence rate of NASH condition is 35.2%, in Chile, it is 23%, in Mexico, it is around 17%, and in Columbia it is around 26.6%. As per NCBI, the prevalence of NASH indication in Middle East & Africa is estimated to reach more than 12,534,000 cases in Saudi Arabia and 372,000 cases in the UAE by 2030. All these statistics are likely to boost the NASH biomarkers market in the region.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Major Players

  • Key players operating in the global non-alcoholic steatohepatitis (NASH) biomarkers market include 
    • Biopredictive
    • Quest Diagnostics
    • Exalenz Bioscience Ltd
    • GENFIT
    • Siemens Healthineers
    • ONE WAY LIVER
    • S.L
    • Prometheus Laboratories Inc
    • Gilead Sciences Ltd.
  • These players are focused on adopting organic and inorganic growth strategies to strengthen product portfolio and expand their alliances with other companies. Key players have adopted strategies such as investment into research & development of efficient non-invasive biomarkers, creating awareness about non-alcoholic steatohepatitis indication, expansion of geographic footprint, and collaborations & acquisitions, in order to be competitive in the global non-alcoholic steatohepatitis (NASH) biomarkers market.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Segmentation

Biomarker Type

Serum Biomarkers

  • Cytokeratin-18 (CK 18)-Biomarker
  • Inflammatory Markers
  • Others

Biomarker Panels

Fibrosis Biomarkers

Imaging Biomarkers

Others

End User

Hospitals

Diagnostic Centers

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Non-alcoholic Steatohepatitis Biomarkers Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Disease Prevalence & Incidence Rate globally with Key countries

    5.2. Regulatory Scenario by Region/globally 

    5.3. Pipeline Analysis 

6. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, by Biomarker Type  

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

        6.3.1. Serum Biomarkers 

            6.3.1.1. Cytokeratin-18 (CK 18) Marker

            6.3.1.2. Inflammatory markers

            6.3.1.3. Others 

        6.3.2. Biomarker Panel  

        6.3.3. Fibrosis Biomarkers

        6.3.4. Imaging Biomarkers 

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Biomarker Type  

7. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, by End-user 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

        7.3.1. Hospitals 

        7.3.2. Diagnostic Centers

        7.3.3. Others

    7.4. Market Attractiveness Analysis, by End-user

8. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, by Region 

    8.1. Key Findings

    8.2. Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe 

        8.2.3. Asia Pacific

        8.2.4. Latin America 

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

    9.1.  Introduction

        9.1.1.  Key Findings

    9.2.  North America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

        9.2.1. Serum Biomarkers 

            9.2.1.1. Cytokeratin-18 (CK 18) Marker

            9.2.1.2. Inflammatory Markers

            9.2.1.3. Others 

        9.2.2. Biomarker Panel  

        9.2.3. Fibrosis Biomarkers

        9.2.4. Imaging Biomarkers 

        9.2.5. Others 

    9.3. North America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

        9.3.1. Hospitals

        9.3.2. Diagnostic Centers

        9.3.3. Others

    9.4. North America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. North America Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

        9.5.1. By Biomarker Type  

        9.5.2. By End-user 

        9.5.3. By Country

10. Europe Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

    10.1.  Introduction

        10.1.1.  Key Findings

    10.2. Europe Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

        10.2.1. Serum Biomarkers 

            10.2.1.1. Cytokeratin-18 (CK 18) Marker

            10.2.1.2. Inflammatory Markers

            10.2.1.3. Others 

        10.2.2. Biomarker Panel  

        10.2.3. Fibrosis Biomarkers

        10.2.4. Imaging Biomarkers 

        10.2.5. Others 

    10.3. Europe Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

        10.3.1. Hospitals

        10.3.2. Diagnostic Centers

        10.3.3. Others

    10.4. Europe Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Europe Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

        10.5.1. By Biomarker Type  

        10.5.2. By End-user 

        10.5.3. By Country/Sub-region

11. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

    11.1.  Introduction

        11.1.1.  Key Findings

    11.2.  Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

        11.2.1. Serum Biomarkers 

            11.2.1.1. Cytokeratin-18 (CK 18) Marker

            11.2.1.2. Inflammatory Markers

            11.2.1.3. Others 

        11.2.2. Biomarker Panel  

        11.2.3. Fibrosis Biomarkers

        11.2.4. Imaging Biomarkers 

        11.2.5. Others 

    11.3. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

        11.3.1. Hospitals 

        11.3.2. Diagnostic Centers

        11.3.3. Others

    11.4. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

        11.5.1. By Biomarker Type  

        11.5.2. By End-user 

        11.5.3. By Country/Sub-region

12. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

    12.1.  Introduction

        12.1.1.  Key Findings

    12.2.  Latin America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

        12.2.1. Serum Biomarkers 

            12.2.1.1. Cytokeratin-18 (CK 18) Marker

            12.2.1.2. Inflammatory Markers

            12.2.1.3. Others 

        12.2.2. Biomarker Panel  

        12.2.3. Fibrosis Biomarkers

        12.2.4. Imaging Biomarkers 

        12.2.5. Others 

    12.3. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

        12.3.1. Hospitals

        12.3.2. Diagnostic Centers

        12.3.3. Others  

    12.4. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

        12.5.1. By Biomarker Type  

        12.5.2. By End-user 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

    13.1.  Introduction

        13.1.1.  Key Findings

    13.2.  Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

        13.2.1. Serum Biomarkers 

            13.2.1.1. Cytokeratin-18 (CK 18) Marker

            13.2.1.2. Inflammatory Markers

            13.2.1.3. Others 

        13.2.2. Biomarker Panel  

        13.2.3. Fibrosis Biomarkers

        13.2.4. Imaging Biomarkers 

        13.2.5. Others 

    13.3. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

        13.3.1. Hospitals

        13.3.2. Diagnostics Centers 

        13.3.3. Others 

    13.4. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

        13.5.1. By Biomarker Type  

        13.5.2. By End-user 

        13.5.3. By Country/Sub-region

14. Competitive Landscape

    14.1.  Market Share Analysis, by Company, 2018

    14.2.  Company Profiles

        14.2.1. Biopredictive 

            14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.1.2. Product Portfolio

            14.2.1.3. Strategic Overview

            14.2.1.4. SWOT Analysis

        14.2.2. Quest Diagnostics

            14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.2.2. Financial Overview

            14.2.2.3. Product Portfolio

            14.2.2.4. Strategic Overview

            14.2.2.5. SWOT Analysis

        14.2.3. Exalenz Bioscience Ltd 

            14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.3.2. Financial Overview

            14.2.3.3. Product Portfolio

            14.2.3.4. Strategic Overview

            14.2.3.5. SWOT Analysis

        14.2.4. GENFIT

            14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.4.2. Financial Overview

            14.2.4.3. Product Portfolio

            14.2.4.4. Strategic Overview

            14.2.4.5. SWOT Analysis

        14.2.5. Siemens Healthineers

            14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.5.2. Financial Overview

            14.2.5.3. Product Portfolio

            14.2.5.4. Strategic Overview

            14.2.5.5. SWOT Analysis

        14.2.6.  ONE WAY LIVER, S.L

            14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.6.2. Product Portfolio

            14.2.6.3. Strategic Overview

            14.2.6.4. SWOT Analysis

        14.2.7.  Prometheus Laboratories Inc.

            14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.7.2. Product Portfolio

            14.2.7.3. Strategic Overview

            14.2.7.4. SWOT Analysis

        14.2.8. Gilead Sciences Ltd.

            14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.2.8.2. Financial Overview

            14.2.8.3. Product Portfolio

            14.2.8.4. Strategic Overview

            14.2.8.5. SWOT Analysis

List of Tables

Table 01: Opportunity Map, by Biomarker Type, 2018

Table 03: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Biomarker Type, 2017–2027

Table 04: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

Table 05: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 06: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Region, 2017–2027

Table 07: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

Table 08: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

Table 09: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 10: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 11: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

Table 12: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

Table 13: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 14: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 15: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

Table 16: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

Table 17: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 18: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 19: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

Table 20: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

Table 21: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 22: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 23: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

Table 24: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

Table 25: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 26: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figures

Figure 01: Global Non-alcoholic Steatohepatitis Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Market Share Analysis, by Region, 2018

Figure 03: Global Non-alcoholic Steatohepatitis Biomarker Market Revenue Projection (US$ Mn), 2017–2027

Figure 04 : Market Value Share, by Biomarker Type, 2018

Figure 05: Market Value Share, by End-user, 2018

Figure 06: Market Value Share, by Region, 2018

Figure 07: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 08: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

Figure 09: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Serum Biomarkers, 2017–2027

Figure 10: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biomarker Panel, 2017–2027

Figure 11: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fibrosis Biomarkers, 2017–2027

Figure 12: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Imaging Biomarkers , 2017–2027

Figure 13: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027

Figure 14: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 15: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

Figure 16: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2019–2027

Figure 17: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diagnostic Centers, 2019–2027

Figure 18: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2019–2027

Figure 19: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Region, 2018 and 2027

Figure 20: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Region, 2019–2027

Figure 21: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

Figure 22: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 23: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

Figure 24: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 25: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

Figure 26: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country, 2018 and 2027

Figure 27: North America Non-alcoholic Steatohepatitis ( NASH) Biomarkers Market Attractiveness, by Country, 2019–2027

Figure 28: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

Figure 29: Europe Non-alcoholic Steatohepatitis ( NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 30: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

Figure 31: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 32: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

Figure 33: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 34: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 35: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

Figure 36: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 37: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

Figure 38: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 39: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

Figure 40: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 41: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 42: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

Figure 43: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 44: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

Figure 45: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 46: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

Figure 47: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 48: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 49: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

Figure 50: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

Figure 51: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

Figure 52: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

Figure 53: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

Figure 54: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 55: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 56: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Position Analysis, by Company (2018)

Figure 57: Quest Diagnostics, Research & Development (US$ Mn), 2016–2018

Figure 58: Quest Diagnostics, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 59: Quest Diagnostics, Breakdown of Net Sales, by Business Segment, 2018

Figure 60: Exalenz Bioscience Ltd , Breakdown of Net Sales, by Region, 2018

Figure 61: Exalenz Bioscience Ltd , Research & Development (US$ Mn), 2016–2018

Figure 62: Exalenz Bioscience Ltd , Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 63: Exalenz Bioscience Ltd , Breakdown of Net Sales, by Business Segment, 2018

Figure 64: GENFIT, Breakdown of Net Sales, by Region, 2018

Figure 65: GENFIT, Research & Development (US$ Mn), 2016–2018

Figure 66: GENFIT, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 67: GENFIT, Breakdown of Net Sales, by Business Segment, 2018

Figure 68: Siemens Healthineers, Breakdown of Net Sales, by Region, 2018

Figure 69: Siemens Healthineers, Research & Development (US$ Mn), 2016–2018

Figure 70: Siemens Healthineers, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 71: Siemens Healthineers, Breakdown of Net Sales, by Business Segment, 2018

Figure 72: Gilead Sciences, Inc., Breakdown of Net Sales, by Region, 2018

Figure 73: Gilead Sciences, Inc., Research & Development (US$ Mn), 2016–2018

Figure 74: Gilead Sciences, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 75: Gilead Sciences, Inc., Breakdown of Net Sales, by Business Segment, 2018

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market